You are seeing the paginated version of the page.
It was specially created to help search engines like Google to build the proper search index.

Click to load the full version of the page
(PDF) Latest statistics on England mortality data suggest systematic mis-categorisation of vaccine status and uncertain effectiveness of Covid-19 vaccination
PDF | The risk/benefit of Covid vaccines is arguably most accurately measured by an all-cause mortality rate comparison of vaccinated against... | Find, read and cite all the research you need on ResearchGate
Original link
40 Places Where Covid Shots Have Failed To Stop The Spread
24 countries and 16 states where cases reached new all-time highs after vaccination roll outs.
Original link
Antibody Evolution after SARS-CoV-2 mRNA Vaccination
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B-cell responses that continue to evolve for at least one year. During that time, memory B cells express increasingly broad and potent antibodies that are resistant to mutations found in variants of concern[1][1]. As a result, vaccination of coronavirus disease 2019 (COVID-19) convalescent individuals with currently available mRNA vaccines produces high levels of plasma neutralizing activity against all variants tested[1][1], [2][2]. Here, we examine memory B cell evolution 5 months after vaccination with either Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) mRNA vaccines in a cohort of SARS-CoV-2 naïve individuals. Between prime and boost, memory B cells produce antibodies that evolve increased neutralizing activity, but there is no further increase in potency or breadth thereafter. Instead, memory B cells that emerge 5 months after vaccination of naïve individuals express antibodies that are equivalent to those that dominate the initial response. We conclude that memory antibodies selected over time by natural infection have greater potency and breadth than antibodies elicited by vaccination. These results suggest that boosting vaccinated individuals with currently available mRNA vaccines would produce a quantitative increase in plasma neutralizing activity but not the qualitative advantage against variants obtained by vaccinating convalescent individuals. ### Competing Interest Statement The Rockefeller University has filed a provisional patent application in connection with this work on which M.C.N.is an inventor (US patent 63/021,387). The patent has been licensed by Rockefeller University to Bristol Meyers Squib. [1]:
ref
-1 [2]:
ref
-2
Original link
Evidence that the mRNA vaccines contain graphene oxide, a poisonous substance | Karen Kingston, former Pfizer employee, current analyst for the pharmaceutical and medical device industries
Original link
Surge in double-jabbed Scots being admitted to hospitals, figures show
ALMOST 300 double-jabbed Scots have been admitted to hospital with Covid over the past month, official figures show. Stats from Public Health Scotland revealed 288 admissions of people who were ful…
Original link
Leak of Pfizer Contract
Thread by @eh_den: PFIZERLEAK: EXPOSING THE PFIZER MANUFACTURING AND SUPPLY AGREEMENT. (thread) Background: Pfizer has been extremely aggressive in trying to protect the details of their international COVID19 vaccin...…
Original link
The Uneasy Case For Universal Vaccinations
Serious medical and legal issues surround the push for mandatory COVID shots.
Original link
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons | NEJM
Original Article from The New England Journal of Medicine — Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons
Original link